Pharming Group N.V. today announced that it has closed a new financing round, comprising three financial instruments and a rights issue, providing a total of €104 million before costs.
Prospectus 2016 is available for download.
Pharming Group N.V. announces the launch of a 1 for 7 Rights Issue of up to 58,943,624 shares to raise approximately €12.1 million to existing shareholders its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016 (the “Transaction”).
Pharming Group N.V. announces its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016.
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.
